Message #21 From:
Stock News Bot Date: July 17, 2006 09:25:00 AM
MCDG News CytoCore Engages Beaufort Advisors as FDA Consultants for Trials and Product Manufacturing
CHICAGO--(BUSINESS WIRE)--July 17, 2006--CytoCore, Inc. (OTCBB:MCDG) announced that it has engaged Beaufort Advisors as its FDA regulatory consultants. CytoCore's CEO David Weissberg stated: "We have essentially completed our financial restructuring efforts and are entering into the next phase of our development activities. We have clinical trials and product manufacturing that we are about to launch. In order to maximize our success with these activities, it requires senior regulatory advice and guidance. We wanted to find a group that had successfully consulted with early stage medical device companies. With Beaufort Advisors, we believe we have a firm that will strongly complement our existing team as we move into the next stage of trials, development, and commercialization of our product portfolio."
"We look forward to working with CytoCore," said Schuyler Ritter, Senior Vice President of Beaufort Advisors, LLC. "We are pleased that our regulatory and clinical trial management experience with in-vitro diagnostics and other medical devices will be available to CytoCore as it develops its screening systems for the early detection of cervical and other cancers."
About Beaufort Advisors LLC
Headquartered in Norfolk, Virginia, Beaufort Advisors LLC specializes in serving the regulatory consulting, clinical trial management, and ongoing quality assurance needs of medical device manufacturers, in-vitro diagnostic device manufacturers and smaller pharmaceutical and biopharma companies. Beaufort Advisors provides full-service clinical research and regulatory compliance support to help its clients get to market as planned, on time and on budget. Beaufort Advisors achieves this objective through strong company leadership that combines seasoned medical industry experts with experienced business professionals to assure a high level of consistently reliable service for its clients. For additional information, please call 757-228-3250 or visit www.beaufortadvisors.com.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
